羟氯喹维持治疗期间突破性 COVID-19 感染 1 例
A Case of Breakthrough COVID-19 during Hydroxychloroquine Maintenance.
机构信息
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
Department of Laboratory Medicine, Seoul National University Hospital, Seoul, Korea.
出版信息
J Korean Med Sci. 2020 Jun 22;35(24):e231. doi: 10.3346/jkms.2020.35.e231.
There have been controversies on the prophylactic effect of hydroxychloroquine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). We describe a patient, 60-year old Korean woman, with coronavirus disease 2019 (COVID-19) who had been taking hydroxychloroquine for 6 months. Her serum and saliva concentrations of hydroxychloroquine were 280 μg/L and 4,890 μg/L, respectively. The present case raises concerns on hydroxychloroquine's role as a prophylactic agent for COVID-19.
羟氯喹对严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的预防作用存在争议。我们描述了一位 60 岁的韩国女性 COVID-19 患者，她已服用羟氯喹 6 个月。她的血清和唾液中羟氯喹的浓度分别为 280μg/L 和 4890μg/L。本病例引起了对羟氯喹作为 COVID-19 预防药物作用的关注。
Zotero 插件